Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 26, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update...
Corcept Therapeutics Announces Final Results of Tender Offer
April 05, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Announces Preliminary Results of Tender Offer
April 03, 2023 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Initiates CATALYST Clinical Trial
March 28, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
March 06, 2023 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of...
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
February 28, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
February 14, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide...
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
February 13, 2023 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Provides Miricorilant Clinical Development Update
December 08, 2022 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
December 08, 2022 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...